ATE164311T1 - Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten - Google Patents

Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten

Info

Publication number
ATE164311T1
ATE164311T1 AT94916352T AT94916352T ATE164311T1 AT E164311 T1 ATE164311 T1 AT E164311T1 AT 94916352 T AT94916352 T AT 94916352T AT 94916352 T AT94916352 T AT 94916352T AT E164311 T1 ATE164311 T1 AT E164311T1
Authority
AT
Austria
Prior art keywords
protein
peptides
pharmaceutical compositions
antibodies
compositions containing
Prior art date
Application number
AT94916352T
Other languages
English (en)
Inventor
Michael Waddington Smith
Original Assignee
Babraham Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Inst filed Critical Babraham Inst
Application granted granted Critical
Publication of ATE164311T1 publication Critical patent/ATE164311T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6943—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a pill, a tablet, a lozenge or a capsule

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT94916352T 1993-06-03 1994-06-02 Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten ATE164311T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939311454A GB9311454D0 (en) 1993-06-03 1993-06-03 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ATE164311T1 true ATE164311T1 (de) 1998-04-15

Family

ID=10736565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94916352T ATE164311T1 (de) 1993-06-03 1994-06-02 Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten

Country Status (9)

Country Link
EP (1) EP0707473B1 (de)
AT (1) ATE164311T1 (de)
AU (1) AU6804394A (de)
DE (1) DE69409237T2 (de)
DK (1) DK0707473T3 (de)
ES (1) ES2117272T3 (de)
GB (1) GB9311454D0 (de)
WO (1) WO1994028879A1 (de)
ZA (1) ZA943920B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ATE235890T1 (de) 1997-01-30 2003-04-15 Chiron Corp Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
EP1275380A1 (de) * 1997-01-30 2003-01-15 Chiron Corporation Verwendung von Mikropartikeln mit adsorbiertem Antigen zur Stimulierung der Immunabwehr
IT1291559B1 (it) * 1997-04-14 1999-01-11 Univ Degli Studi Milano Uso di microparticelle su cui sono stati adsorbiti una proteina ed un anticorpo per preparare una composizione farmaceutica somministrabile
MXPA03002643A (es) 2000-09-28 2003-06-19 Chiron Corp Composiciones de microparticulas y metodos para producirlas.
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
EP1900753B1 (de) 2002-11-08 2017-08-09 Ablynx N.V. Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
EP1558645B1 (de) 2002-11-08 2011-07-27 Ablynx N.V. Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2595826B1 (fr) * 1986-03-13 1990-09-07 Lurhuma Zirimwabagabo Produit d'immuno-essai, son procede de preparation, son utilisation, complexe immunogene le comportant et utilisation de ce complexe
HK1002252A1 (en) * 1991-04-02 1998-08-07 Biotech Australia Pty. Limited Oral delivery systems for microparticles

Also Published As

Publication number Publication date
DE69409237T2 (de) 1998-10-29
ZA943920B (en) 1995-12-04
GB9311454D0 (en) 1993-07-21
ES2117272T3 (es) 1998-08-01
EP0707473A1 (de) 1996-04-24
EP0707473B1 (de) 1998-03-25
DK0707473T3 (da) 1999-01-04
WO1994028879A1 (en) 1994-12-22
AU6804394A (en) 1995-01-03
DE69409237D1 (de) 1998-04-30

Similar Documents

Publication Publication Date Title
NO962346L (no) Humaniserte antistoffer og anvendelser derav
BG60256B1 (bg) Рекомбинантен метод за получаване на лимфотоксин
ATE164311T1 (de) Orale, pharmazeutische zusammensetzungen das ein protein oder peptide, eine antikoerper und polymerkugeln enthalten
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
ATE189611T1 (de) Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten
BR8906988A (pt) Tetrapiptidio,peptidio,composicao farmaceutica,processo para uso de peptidio e reagente para diagnostico
DK184890D0 (da) Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme
DK614987A (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
ATE132197T1 (de) Monoklonale antikörper
IL96907A0 (en) Proteins produced by human lymphocytes,a dna sequence coding for said proteins and their pharmaceutical and biological application
DK110183D0 (da) Carboxyalkyldipeptider, fremgangsmade til deres fremstilling samt farmaceutiske praeparater indeholdende disse
NL194828B (nl) Somatostatinepeptiden, alsmede dergelijke somatostatinepeptiden bevattende farmaceutische preparaten.
KR900013979A (ko) 사람 유두종비루스형 16의 e7 단백질상의 면역원성 영역
BR9810907A (pt) Anticorpos monoclonais e policlonais, peptìdeo suscetìvel de gerar um anticorpo, agente imunogênico, sequência de nucleotìdeos, composição farmacêutica, uso de pelo menos um anticorpo, kit de diagnóstico, e, processo para preparar um agente imunogênico
FR2577557B1 (fr) Peptides et derives peptidiques, leur preparation, leur utilisation en therapeutique et compositions pharmaceutiques les contenant
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
ATE48142T1 (de) Blutprotein, verfahren zu seiner herstellung, antikoerper gegen dieses protein und dieses protein oder diese antikoerper enthaltende pharmazeutische zubereitungen.
ES2085329T3 (es) Agente anticanceroso proteico.
HUP9800613A2 (hu) Humán Fas-antigén elleni humanizált antitest
ATE67210T1 (de) Androstane-17-beta-carbonsaeureester, verfahren zu deren herstellung und pharmazeutische praeparate die diese enthalten.
AR004377A1 (es) UNA PROTEINA BIOLOGICAMENTE ACTIVA INHIBIDORA DE KAPA B (NF k B), UNA SECUENCIA DE ACIDO NUCLEICO, UN VECTOR DE EXPRESION, UN ANTICUERPO CONTRADICHA PROTEINA, UN PROCESO PARA SU PREPARACION, UNA COMPOSICION FARMACEUTICA Y EL USO DE DICHA PROTEINA PARA LA PREPARACION DE COMPOSICIONES FARMACEUTICAS.
CA2139518A1 (en) Antigenic regions of tlp complexes and antibodies against the same
KR900701300A (ko) 생물학적 활성 펩티드 및 특정음이온을 갖는 조성물 및 이것을 사용하는 방법
NO890174L (no) Rekombinante interleukin-1alfa-polypeptider.
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee